MAPT and Alzheimer disease: In the current study, leflunomide showed a therapeutic and neuroprotective effect in AlCl3-induced AD in rats by its ability to improve learning behavior, diminish Aβ and tau burden, decrease the hippocampal AChE activity, and hamper NF-κβ, TNF-α, and IL-1β concentrations.